However, there is still a subset of patients with PD-L1-negative and/or TMB-low tumours responding to ICB and another subset of patients with both PD-L1-positive and TMB-high tumours manifesting resistance to ICB [4, 26]. The gene discussed is CD274; the disease is neoplasm.